Display options
Cite
Liu YL, Zhang HM, Pan HM, et al. The relationship between apolipoprotein E gene ε2/ε3/ε4 polymorphism and breast cancer risk: a systematic review and meta-analysis. Onco Targets Ther. 2016;9:1241-9doi: 10.2147/OTT.S94228.
Liu, Y. L., Zhang, H. M., Pan, H. M., Bao, Y. H., Xue, J., Wang, T. C., Dong, X. C., Li, X. L., & Bao, H. G. (2016). The relationship between apolipoprotein E gene ε2/ε3/ε4 polymorphism and breast cancer risk: a systematic review and meta-analysis. OncoTargets and therapy, 91241-9. https://doi.org/10.2147/OTT.S94228
Liu, Yun-Long, et al. "The relationship between apolipoprotein E gene ε2/ε3/ε4 polymorphism and breast cancer risk: a systematic review and meta-analysis." OncoTargets and therapy vol. 9 (2016): 1241-9. doi: https://doi.org/10.2147/OTT.S94228
Liu YL, Zhang HM, Pan HM, Bao YH, Xue J, Wang TC, Dong XC, Li XL, Bao HG. The relationship between apolipoprotein E gene ε2/ε3/ε4 polymorphism and breast cancer risk: a systematic review and meta-analysis. Onco Targets Ther. 2016 Mar 07;9:1241-9. doi: 10.2147/OTT.S94228. eCollection 2016. PMID: 27022282; PMCID: PMC4789883.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2016 Mar 07;9:1241-9. doi: 10.2147/OTT.S94228. eCollection 2016.

The relationship between apolipoprotein E gene ε2/ε3/ε4 polymorphism and breast cancer risk: a systematic review and meta-analysis.

OncoTargets and therapy

Yun-Long Liu, Hao-Min Zhang, Hong-Ming Pan, Yu-Hang Bao, Jing Xue, Tian-Chang Wang, Xiao-Cheng Dong, Xiao-Ling Li, Hong-Guang Bao

Affiliations

  1. Department of Chest Surgery, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, Heilongjiang, People's Republic of China.
  2. Basic Medical Science College, Qiqihar Medical University, Qiqihar, Heilongjiang, People's Republic of China.
  3. Department of Anatomy, Basic Medical Science College, Qiqihar Medical University, Qiqihar, Heilongjiang, People's Republic of China.

PMID: 27022282 PMCID: PMC4789883 DOI: 10.2147/OTT.S94228

Abstract

OBJECTIVE: We conducted a systematic review and meta-analysis aiming to assess the relationship between apolipoprotein E (APOE) gene ε2/ε3/ε4 polymorphism and breast cancer risk.

METHODS: Yun-Long Liu and Hao-Min Zhang independently completed literature retrieval and data collection, and statistical analyses were performed by Stata. Individual odds ratio (OR) and 95% confidence interval (CI) were pooled in a random-effects model using the DerSimonian-Laird method. Heterogeneity was evaluated by I (2) statistic at a significance level of 50%. Publication bias was assessed by Egger's test.

RESULTS: Eleven articles including 2,074 breast cancer patients and 2,372 controls were summarized. Using the most common allele ε3 as a reference, the ε2 (OR =0.87, 95% CI =0.72-1.05, P=0.154, I (2)=0.0%) and ε4 (OR =1.07, 95% CI =0.80-1.42, P=0.654, I (2)=71.8%) alleles were not found to be significantly associated with breast cancer risk in the overall analyses. Subgroup analyses revealed that the comparison of allele ε4 with ε3 was significant in Asians (OR =1.58, 95% CI =1.17-6.32, P=0.003, I (2)=12.1%) and in studies that used the restriction fragment length polymorphism (RFLP) genotyping method (OR =1.27; 95% CI =1.01-1.61, P=0.045, I (2)=34.3%), and was marginally significant in hospital-based studies (OR =1.33; 95% CI =0.98-1.79, P=0.065, I (2)=30.2%), without heterogeneity. Moreover, the presence of the ε2 allele was significantly associated with breast cancer in small studies (total sample size <500) (OR =0.73, 95% CI =0.54-1.00, P=0.052, I (2)=0.0%) without heterogeneity. The Egger's test indicated low probabilities of publication bias.

CONCLUSION: We observed a significant association between APOE gene ε4 allele and breast cancer risk in Asian populations. Moreover, the findings of our subgroup analyses suggest that source of controls, genotyping platform, and sample size might be the potential causes of heterogeneity.

Keywords: apolipoprotein E; breast cancer; meta-analysis; polymorphism

References

  1. Breast Cancer Res Treat. 2005 Apr;90(3):257-61 - PubMed
  2. Mol Carcinog. 2000 Jan;27(1):2-9 - PubMed
  3. Breast Cancer Res. 2013 Dec 20;15(6):212 - PubMed
  4. Breast Cancer Res Treat. 2006 Jul;98(1):109-13 - PubMed
  5. Am J Ophthalmol. 2004 Oct;138(4):567-73 - PubMed
  6. Onco Targets Ther. 2015 Jan 29;8:279-87 - PubMed
  7. Int J Hypertens. 2011;2011:653698 - PubMed
  8. Br J Cancer. 2004 May 17;90(10):1989-94 - PubMed
  9. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  10. Breast Cancer (Auckl). 2010 May 24;4:43-8 - PubMed
  11. Nat Genet. 1996 Sep;14(1):55-61 - PubMed
  12. Biometrics. 2000 Jun;56(2):455-63 - PubMed
  13. Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1112-9 - PubMed
  14. Am J Hum Genet. 1980 May;32(3):339-47 - PubMed
  15. J Clin Oncol. 2014 Jun 20;32(18):1909-18 - PubMed
  16. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  17. Mol Cell Probes. 1994 Dec;8(6):519-25 - PubMed
  18. Tumour Biol. 2014 Aug;35(8):7699-705 - PubMed
  19. Cancer Genet Cytogenet. 2003 Oct 1;146(1):86-7 - PubMed
  20. Mol Clin Oncol. 2014 Nov;2(6):1009-1015 - PubMed
  21. BMC Med Res Methodol. 2011 Apr 07;11:41 - PubMed
  22. J Cancer Res Clin Oncol. 2014 Jul;140(7):1075-85 - PubMed
  23. Cancer Res. 2005 Jan 1;65(1):331-7 - PubMed
  24. J Clin Invest. 1984 Apr;73(4):1024-33 - PubMed
  25. Mol Med Rep. 2015 Sep;12(3):3476-86 - PubMed
  26. J Epidemiol Community Health. 2000 Dec;54(12):938-9 - PubMed
  27. Cancer Res Treat. 2012 Jun;44(2):121-6 - PubMed
  28. Eur J Intern Med. 2002 Feb;13(1):37-43 - PubMed
  29. Brain Behav Immun. 2013 Mar;30 Suppl:S117-25 - PubMed

Publication Types